{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:04:32Z","timestamp":1778875472476,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.breast.2018.04.011","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T22:23:57Z","timestamp":1524090237000},"page":"45-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey"],"prefix":"10.1016","volume":"40","author":[{"given":"Marta","family":"Bonotto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debora","family":"Basile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Gerratana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Pelizzari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Bartoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Grazia","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Fanotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Lisanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Mansutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro Marco","family":"Minisini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Aprile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"De Laurentiis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Montemurro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Del Mastro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"67","key":"10.1016\/j.breast.2018.04.011_bib1","first-page":"7","article-title":"Cancer statistics","volume":"2017","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.breast.2018.04.011_bib2","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/cncr.22867","article-title":"The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer","volume":"110","author":"Chia","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2018.04.011_bib3","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1634\/theoncologist.2014-0002","article-title":"Measures of outcome in metastatic breast cancer: insights from a real-world scenario","volume":"19","author":"Bonotto","year":"2014","journal-title":"Oncol"},{"key":"10.1016\/j.breast.2018.04.011_bib4","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.breast.2016.10.021","article-title":"Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: a propensity score analysis","volume":"31","author":"Bonotto","year":"2017","journal-title":"Breast"},{"key":"10.1016\/j.breast.2018.04.011_bib5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/annonc\/mdt429","article-title":"Metastatic breast cancer: are we treating the same patients as in the past?","volume":"25","author":"Ufen","year":"2014","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.breast.2018.04.011_bib6","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.breast.2018.04.011_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10585-015-9697-2","article-title":"Pattern of metastasis and outcome in patients with breast cancer","volume":"32","author":"Gerratana","year":"2015","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.breast.2018.04.011_bib8","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1634\/theoncologist.2015-0002","article-title":"Treatment of metastatic breast cancer in a real-world scenario: is progression-free survival with first line predictive of benefit from second and later lines?","volume":"20","author":"Bonotto","year":"2015","journal-title":"Oncol"},{"key":"10.1016\/j.breast.2018.04.011_bib9","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/jnci\/djk091","article-title":"When you look matters: the effect of assessment schedule on progression-free survival","volume":"99","author":"Panageas","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"45","key":"10.1016\/j.breast.2018.04.011_bib10","first-page":"228","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"2009","author":"Eisenhauer","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.breast.2018.04.011_bib11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2018.04.011_bib12","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1200\/JCO.2016.66.6313","article-title":"Use and costs of disease monitoring in women with metastatic breast cancer","volume":"34","author":"Accordino","year":"2016","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.breast.2018.04.011_bib13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.lungcan.2016.08.002","article-title":"Scan-associated distress in lung cancer: quantifying the impact of \u201cscanxiety.\u201d","volume":"100","author":"Bauml","year":"2016","journal-title":"Lung Cancer Amst Neth"},{"key":"10.1016\/j.breast.2018.04.011_bib14","unstructured":"NCCN Clinical Practice Guidelines in Oncology n.d. https:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp (accessed June 6, 2017)."},{"key":"10.1016\/j.breast.2018.04.011_bib15","article-title":"3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)","author":"Cardoso","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.breast.2018.04.011_bib16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.breast.2013.03.006","article-title":"International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)\u2013MBC Task Force: surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer","volume":"22","author":"Lin","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.breast.2018.04.011_bib17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.6004\/jnccn.2017.0021","article-title":"Identifying educational needs of the multidisciplinary cancer team in the treatment of metastatic breast cancer","volume":"15","author":"Wanchoo","year":"2017","journal-title":"J\u00a0Natl Compr Cancer Netw JNCCN"},{"key":"10.1016\/j.breast.2018.04.011_bib18","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1200\/JCO.2016.66.6313","article-title":"Use and costs of disease monitoring in women with metastatic breast cancer","volume":"34","author":"Accordino","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2018.04.011_bib19","doi-asserted-by":"crossref","first-page":"316","DOI":"10.6004\/jnccn.2017.0031","article-title":"Patterns of utilization of imaging studies and serum tumor markers among patients with de novo metastatic breast cancer","volume":"15","author":"Di Meglio","year":"2017","journal-title":"J\u00a0Natl Compr Cancer Netw JNCCN"},{"key":"10.1016\/j.breast.2018.04.011_bib20","unstructured":"www.evtel.com ET-. Linee Guida. Aiom n.d. http:\/\/www.aiom.it\/professionisti\/documenti-scientifici\/linee%2dguida\/1,413,1, (accessed May 30, 2017)."},{"key":"10.1016\/j.breast.2018.04.011_bib21","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1200\/JCO.2015.61.1459","article-title":"Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American society of clinical Oncology clinical practice guideline","volume":"33","author":"Van Poznak","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2018.04.011_bib22","first-page":"58","article-title":"Current approaches and challenges in monitoring treatment responses in breast cancer","volume":"5","author":"Graham","year":"2014","journal-title":"J\u00a0Canc"},{"key":"10.1016\/j.breast.2018.04.011_bib23","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1001\/jama.2010.460","article-title":"Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006","volume":"303","author":"Dinan","year":"2010","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.breast.2018.04.011_bib24","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1001\/jama.1994.03510440047031","article-title":"Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: a multicenter randomized controlled trial","volume":"271","author":"Ghezzi","year":"1994","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.breast.2018.04.011_bib25","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1200\/JCO.2014.56.2561","article-title":"Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500","volume":"32","author":"Smerage","year":"2014","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.breast.2018.04.011_bib26","unstructured":"The Italian Medicines Agency | AIFA Agenzia Italiana del Farmaco n.d. http:\/\/www.aifa.gov.it\/en\/node\/4111 (accessed July 24, 2017)."},{"key":"10.1016\/j.breast.2018.04.011_bib27","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2018.04.011_bib28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2014.0008","article-title":"Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy","volume":"12","author":"Seah","year":"2014","journal-title":"J\u00a0Natl Compr Cancer Netw JNCCN"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977618300742?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977618300742?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:38:51Z","timestamp":1760776731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977618300742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":28,"alternative-id":["S0960977618300742"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2018.04.011","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2018.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}